Welcome to Nofinity

This transcript summarizes a conversation about endometriosis and adenomyosis, two related but distinct uterine conditions.

Endometriosis: The Basics

• Definition: Tissue similar to the uterine lining (endometrium) grows outside the uterus, e.g., on fallopian tubes, ovaries, bladder, or bowel.
• Prevalence: Affects ~10% of reproductive-age women (≈200 million globally). Among infertile women, the rate is 30-50%.
• Symptoms (The '6 Ds'): Dysmenorrhea (painful periods), Deep Dyspareunia (pain during sex), Dyschezia (pain with bowel movements), Dysuria (pain with urination), Infertility (difficulty conceiving), and chronic pelvic pain.
• Pain Mechanisms: Three types: nociceptive (direct from lesion), neuropathic (nerve infiltration), and nociplastic (central sensitization – the pain system is stuck in 'on' mode).

Causes & Risk Factors

• Genetics: ~50% heritable; 7x higher risk if a mother/sister is affected.
• Retrograde Menstruation: 90% of women have some backward flow of menstrual blood. Normally cleared by the immune system; in endometriosis, this clearance is impaired.
• Modern Lifestyle: Today's women have ~400 menstrual cycles (vs. ~100 historically). Fewer pregnancies, shorter breastfeeding, and earlier first period (age 12 vs. 16) drastically increase retrograde flow events.

Adenomyosis vs. Endometriosis

• Adenomyosis: Endometrial-like tissue grows within the uterine muscle (myometrium). Previously called 'internal endometriosis.'
• Prevalence: Even more common than endometriosis (20-30% of women). Up to 70% of endometriosis patients also have adenomyosis.
• Symptoms: Mostly heavy bleeding and painful periods. Caused by tissue injury and repair (TIA) as tissue invades the junctional zone.
• Comparison to Fibroids: Fibroids are benign nodules that are often asymptomatic and can disrupt anatomy. They are not the same as adenomyosis or endometriosis.

Diagnosis: Early Detection is Key

• Problem: Diagnostic delay is 5-12 years (≈6 years in the US). Reasons: normalization of pain, lack of a blood test, reliance on surgery (laparoscopy) for diagnosis.
• New Guidelines (ACOG, March 2025): Allow for a clinical diagnosis based on symptoms and treatment without upfront surgery. Goal: shorten suffering.
• Imaging: Specialized transvaginal ultrasound (with bowel prep) and MRI (non-contrast, T1/T2) can now detect >95% of deep lesions. Standard ultrasound has low sensitivity.
• Key Takeaway: 'If you have pain and a normal ultrasound report says you don't have endometriosis, don't believe it. You need a specialized exam.'

Treatment & Fertility

Medical (for pain, not trying to conceive):

• First-line: Birth control pills (low-dose estrogen + progestin) or progestin-only (e.g., Dienogest pill, Mirena IUD). They suppress ovulation and menstruation to calm the lesions.
• If resistant: Consider surgery (laparoscopy). Crucial: Start medication immediately post-surgery, or recurrence is 10% per year.

Fertility (in IVF context):

• Main obstacle: Mechanical (blocked tubes) rather than biological (egg quality is similar). The uterine lining is likely not the main problem.
• Surgery before IVF: Helpful for large endometriomas (>5-6 cm), but risk: removing healthy ovarian tissue.
• Adenomyosis & IVF: The diseased uterus disrupts implantation and can cause miscarriage (especially at 6-8 weeks). Solution: Medically shut down the ovaries (e.g., with GnRH agonists like Leuprolide) for 2-4 months to calm the uterus. Success rates then become similar to women without adenomyosis.

Common mistakes:

• Operating when central sensitization is already present (surgery won't fix that pain).
• Removing endometriomas before egg retrieval (significantly lowers ovarian reserve).
• Not removing damaged fallopian tubes (hydrosalpinx): they secrete toxins that reduce implantation by up to 50%.

Emerging Treatments

• Biologics: HMI115 (antibody targeting prolactin receptor) is in phase 3 trials. Could be the first non-hormonal treatment for endometriosis.
• Awareness: Pushing for earlier diagnosis and better funding (currently 15x less than for diabetes) is seen as critical.

• If you suffer from pelvic pain, painful periods, or pain during sex/bowel movements, don't take 'no' for an answer. Insist on specialized imaging (e.g., MRI or expert protocol ultrasound).
• A diagnosis is not a dead end but the start of a plan. 'Patients often cry from relief when they finally hear their pain has a name.'
• Early treatment prevents not only unnecessary suffering but preserves fertility and prevents painful brain rewiring (central sensitization).

Keywords: Endometriosis, Adenomyosis, Retrograde Menstruation, Endometrium, Infertility, IVF, Pelvic Pain, GnRH Agonist

Summary follows...

Summary follows...

Summary follows...

The market witnessed an extreme recovery after one of the worst Julys for AI stocks: within two days, 70–75% of the damage was reversed – a classic FOMO chase. The analyst reviews last week's predictions and answers community questions.

Major Indices & Commodities

• VIX: Peaked at 20.66 on July 29 – a perfect sell signal. Today, an unexplained spike to the 200-day moving average. - QQQ (Nasdaq 100): Hit the 200 EMA (662) as support and bounced back to 722. Violent swings are a trader's paradise. - S&P 500: New all-time high; P/E of 20 – historically cheap. No bubble, AI is transforming everything. - Gold: Strong day after Yen and Indian Rupee needed bailouts. Fiat is going to zero – bullish for Bitcoin. - Copper: New all-time high (68,278) – driven by AI and electrification.

Cryptocurrencies

• Bitcoin: Stuck at ~$64K since February, strong support at $59K. Buy signal active. Sideways until ETF and MicroStrategy buy aggressively. - Ethereum: 8% below the 200-day MA (2,085). Once broken, it could surge to $4,000–5,000. - Solana: “Sucking wind” – no major movement. Above the 200-day MA ($85). Dominant L1 with 3.5M users vs. 800K for Sui and 7M transactions vs. 76M for Solana. - MicroStrategy (MSTR): Selling shares (ATM) into strength to support STRK. Needs STRK at $100 to restart the Bitcoin buying flywheel. - Jupiter, Hyperliquid, Bittensor: Analyst is skeptical – Bittensor due to tokenomics, Jupiter dead because of missing AI hype, Hyperliquid lacks a moat.

Stocks in Focus

• Tesla (TSLA): Disappointing; retail hesitates due to Cybercab and SpaceX confusion. Institutions buy. Support at $298–297 held. - SpaceX/Tesla Pair: Ratio 2.6–2.973 – ideal for tax-free pair trades. - Nvidia (NVDA): Strong recovery from $190, new ATH at $5.31T market cap. P/E at all-time low – never cheaper. Elon Musk buys only Nvidia for SpaceX. - Micron (MU): Recovered from $739 to $920. On track to $1,600. - Marvell (MRVL): Jumped from $164 to $219 (36.7% in two days) – now consolidating. - Google (GOOGL): Strange day: rumor of AI researchers leaving dropped stock from $382 to $355. Undervalued vs. Microsoft (better financials, faster cloud growth). - AMD: From $420 back to $480 – AI spending continues rising. - Broadcom (AVGO): Buy signal at $369, sell signal at $430 – now heading to new ATH. - Palantir (PLTR): Buy zone at $106, but range-bound since February. 200-day MA pointing down ($152) – caution on profit-taking. - Unusual Machines (UMAC): Small drone play with strong financials – preferred over Anduril. - Corning (GLW): P/E of 73 – too expensive vs. Micron (P/E 5).

Q&A Highlights

• Layer-1 alternatives: Sui and Sei have fewer users than Solana – Solana remains the winner. - Hype (HYPE): New ATH at $77, buy signal at $50 – few users but high revenue. - Anduril (ANDR): Financials improved – could be worth a look. - Trading tips: Use Heikin-Ashi for noise reduction, trend and ATR models for precise signals (e.g., on ALAB). - Risk management: Option strategy (selling puts to buy leaps) can yield 9x but also ruin you.

Bottom line: Markets are extremely volatile, but AI stocks are fundamentally cheap. Those who model the big swings can achieve excellent returns. The analyst stays focused on AI, copper, and Solana – with caution on Palantir and smaller crypto projects.

• The speaker analyzes the current gold price correction and provides an update for the Gold Path 2026.
• Despite fears and a drop, he believes the long-term bull market remains intact.

• In gold bull markets, prices often revisit the 20-month SMA or 21-month EMA, as seen in the 2000s and 1970s.
• The bull market support band (20-month SMA + 21-month EMA) has not been touched yet – a sign of strength.
• Commodity markets move slower than crypto or stocks, so long-term moving averages are relevant.

• The 2026 year-to-date (YTD) return closely tracks 2022 and 2018 – both years saw subsequent recoveries.
• In midterm years (like 2026), gold typically bottoms between June and October.
• Corrections of 20–30% are normal in bull markets (e.g., 1970s and 2000s).

• The average of all prior midterm years shows a low in early July.
• A potential further dip could be linked to a stronger US dollar (similar to 2018).
• If the dollar rises in 1–2 months, gold might weaken again – but as a higher low or lower low.

• The speaker remains bullish on gold – the current weakness is a normal consolidation.
• After the 2026 bottom, he expects a final rally towards the end of the decade, followed by a global top.
• Historical patterns suggest a strong 2027 (pre-election year), with an average gain of +13%.
• The ITC conference in November will provide further insights on gold and other asset classes.

This video breaks down the real reasons behind the stalled Clarity Act for crypto regulation, focusing on a single unanswered document that has been sitting in the White House since July 30.

• The Core Conflict: A compromise proposal by Senators Tillis and Gálvez would ban federal officials (and their spouses) from issuing or sponsoring digital assets while in office, enforced by the Attorney General. The White House has not responded.
• The Stalemate: The bill needs 60 Senate votes but is blocked by exactly seven Democrats who demand stricter ethics rules – the very rules the President won't sign.
• The Conflict of Interest: A Senate Banking Committee minority report reveals the Trump family earned over $1.4 billion in crypto income in 2025 – about 23% of the President's reported income. The ethics clause would directly affect this revenue.
• Who's Not Blocking: Wall Street (BlackRock, Fidelity, Goldman Sachs) and community banks publicly support the bill, seeking only minor tweaks. Blaming Elizabeth Warren or the banking sector is a distraction.
• Market Impact: Bitcoin is flat, while Coinbase and Circle have lost value. Analysts see a